Jazz Pharmaceuticals (NASDAQ:JAZZ) SVP Mary Elizabeth Henderson Sells 5,343 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Mary Elizabeth Henderson sold 5,343 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the transaction, the senior vice president owned 28,728 shares in the company, valued at approximately $5,587,308.72. The trade was a 15.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mary Elizabeth Henderson also recently made the following trade(s):

• On Tuesday, December 9th, Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $190.46 on Tuesday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The company has a market cap of $11.72 billion, a P/E ratio of -31.90, a price-to-earnings-growth ratio of 0.38 and a beta of 0.22. The business’s fifty day moving average is $170.05 and its 200-day moving average is $152.44.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm earned $6.51 earnings per share. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Analysts Set New Price Targets

JAZZ has been the subject of a number of analyst reports. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday, January 12th. Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Bank of America raised their price objective on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company boosted their target price on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $214.57.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in JAZZ. Farther Finance Advisors LLC lifted its position in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $36,000. Hantz Financial Services Inc. raised its holdings in Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 297 shares in the last quarter. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $38,000. Finally, Danske Bank A S bought a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $40,000. Institutional investors own 89.14% of the company’s stock.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Barclays started research coverage of Jazz, which can increase visibility and liquidity for the stock and sometimes leads to upgrades or renewed investor interest. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: A Zacks report examines Jazz’s dependence on international sales and the implications for analyst forecasts and the company’s growth outlook — useful background but not an immediate catalyst unless the analysis triggers revisions to guidance or estimates. Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
• Negative Sentiment: Executive vice president Neena M. Patil sold 55,600 shares (≈$10.65M at ~$191.56/share), a nearly 50% reduction in her stake — a large single insider sale that may weigh on sentiment. Neena M. Patil SEC Filing
• Negative Sentiment: Additional senior insider sales: SVP Mary Elizabeth Henderson sold 5,343 shares (~$1.04M) and Director Norbert G. Riedel sold 3,415 shares (~$655.7K); CAO Patricia Carr executed two smaller sales on Feb. 26–27. Collectively these transactions represent meaningful percentage reductions in holdings by multiple insiders and may be interpreted as a near-term negative signal by some investors. Mary E. Henderson SEC Filing Norbert G. Riedel SEC Filing Patricia Carr SEC Filing

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.